EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority

Hakim-Moulay Dehbi iD, Sean Devlins, Alexia Iasonos iD, Matthew Nankivell, Duncan Gilbert, John O'Quigley

Statistics in Medicine · 2025

DOI: 10.1002/sim.70118 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Hakim-Moulay Dehbi and 5 co-authors. Institution: Comprehensive Clinical Trials Unit, University College London, London, UK. Major MEDLINE topics: Antineoplastic Agents, Equivalence Trials as Topic. Cited 1 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

A dose optimization trial in oncology may be performed to compare an approved dose level of a given drug with a reduced dose level, testing the hypothesis that efficacy is maintained whilst reducing side effects and consequently improving adherence and quality‐of‐life. This is particularly relevant with modern therapeutic agents whose mechanisms of action imply that efficacy may not necessarily be linearly related to the dose. Using a conventional non‐inferiority framework leads to large sample sizes that are often unfeasible in the phase IV setting. An alternative is to use a margin of practical non‐inferiority, which we define in this paper and show how it can be exploited to justify a sample size. Whilst defining the extent of the margin, researchers also pre‐specify the other dimensions of interest, such as receptor occupancy and/or side effects and quality‐of‐life, that will be used to establish practical non‐inferiority if the observed efficacy of the reduced dose level lies within the margin. The comparison of efficacy is based on the observed difference between the reduced and the approved levels, instead of the confidence interval of this difference, leading to a reduction in sample size. The reduction in precision due to the smaller sample size is compensated by formally pre‐specifying the additional dimensions to the decision process, allowing a more thorough assessment of the opportunity to reduce a dose in practice, with the many advantages that this may involve.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsEquivalence Trials as TopicSample SizeHumansDose-Response Relationship, DrugQuality of LifeComputer SimulationModels, StatisticalNeoplasms

Author keywords

dosedose optimizationdose reductionrandomized trialsample size calculation

Substances

Antineoplastic Agents

Authors and institutions

  • Comprehensive Clinical Trials Unit, University College London, London, UK.
  • Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
  • MRC Clinical Trials Unit, University College London, London, UK.

ORCID profiles: Hakim-Moulay Dehbi, Alexia Iasonos

Funding

  • NCI NIH HHS

Cite

APA

Dehbi, H. M., Devlins, S., Iasonos, A., Nankivell, M., Gilbert, D., & O'Quigley, J. (2025). Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority. Statistics in Medicine. https://doi.org/10.1002/sim.70118

Vancouver

Dehbi HM, Devlins S, Iasonos A, Nankivell M, Gilbert D, O'Quigley J. Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority. Statistics in Medicine. 2025. doi:10.1002/sim.70118

BibTeX
@article{Dehbi2025,
  author = {Dehbi, Hakim-Moulay and Devlins, Sean and Iasonos, Alexia and Nankivell, Matthew and Gilbert, Duncan and O'Quigley, John},
  title = {Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70118}
}
Start for free →